Evaluation of adamantane hydroxamates as botulinum neurotoxin inhibitors: Synthesis, crystallography, modeling, kinetic and cellular based studies
作者:Peter Šilhár、Nicholas R. Silvaggi、Sabine Pellett、Kateřina Čapková、Eric A. Johnson、Karen N. Allen、Kim D. Janda
DOI:10.1016/j.bmc.2012.12.001
日期:2013.3
Botulinum neurotoxins (BoNTs) are the most lethal biotoxins known to mankind and are responsible for the neuroparalytic disease botulism. Current treatments for botulinum poisoning are all protein based and thus have a limited window of treatment opportunity. Inhibition of the BoNT light chain protease (LC) has emerged as a therapeutic strategy for the treatment of botulism as it may provide an effective
肉毒杆菌神经毒素 (BoNT) 是人类已知的最致命的生物毒素,是导致神经麻痹性疾病肉毒中毒的原因。目前对肉毒杆菌中毒的治疗都是基于蛋白质的,因此治疗机会窗口有限。抑制 BoNT 轻链蛋白酶 (LC) 已成为治疗肉毒杆菌中毒的一种治疗策略,因为它可以提供有效的暴露后补救措施。结合结晶学和模型研究,制备了一系列衍生自 1-金刚烷基乙酰异羟肟酸 ( 3a )的异羟肟酸酯。从这组化合物中,观察到两种衍生物的效力提高了约 17 倍。对这些结构的详细机理研究揭示了一个竞争性抑制模型,K i = 27 nM,这使得这些化合物成为迄今为止报道的最有效的小分子非肽类 BoNT/A LC 抑制剂。